Bayer raises class fund for future Roundup claims to $2bn
Sarah JollyFebruary 4, 2021
German pharmaceuticals firm Bayer has increased funds to settle future claims in the US that its weedkiller product Roundup causes cancer to $2bn, after its opening bid of $1.25bn was rejected by a judge last year.
The new...
Want to read this article?
Register for ultimate access to this article and ALL our premium content
ULTIMATE ACCESS PROVIDES YOU WITH
- Unrestricted access to Commercial Risk, Commercial Risk Europe and Global Risk Manager news, exclusive expert analysis and opinion
- Breaking news, daily and/or weekly Commercial Risk Europe newsletters and regular digital publications
- Breaking news, weekly and monthly Global Risk Manager newsletters and quarterly digital Journal
- European and global surveys, rankings and special reports
- National European local language newsletters
- Preferential access to webinars and virtual and physical conferences
If you are already a registered user or subscriber you can LOGIN below for ultimate access:
Sarah JollyFebruary 4, 2021